← Human Trials & Peer-Reviewed Studies
PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment
Plain-language guide to PMID 23649554 (2013): placebo-controlled randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 38 patients.
Key Facts
- PMID
- 23649554
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Sikjaer T et al. (6 authors)
- DOI
- 10.1002/jbmr.1964
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.
Untreated, hypoparathyroidism (hypoPT) is a state of hypocalcemia with inappropriately low plasma parathyroid hormone (PTH) levels and hyperphosphatemia.
PTH levels rose immediately, reaching a median peak level of 26.5 (interquartile range [IQR], 20.1-42.5) pmol/L 15 minutes following injection.
Who Took Part
The study group was 38 patients.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.
What Was Measured
Untreated, hypoparathyroidism (hypoPT) is a state of hypocalcemia with inappropriately low plasma parathyroid hormone (PTH) levels and hyperphosphatemia.
PTH levels rose immediately, reaching a median peak level of 26.5 (interquartile range [IQR], 20.1-42.5) pmol/L 15 minutes following injection.
The subject headings attached to it are Biomarkers, Blood Pressure, Circadian Rhythm, Electrocardiography, Hormone Replacement Therapy, Hypoparathyroidism and Magnesium.
The authors tagged it with the keywords CALCIUM/PHOSPHATE DISORDERS, CLINICAL TRIALS, HORMONES AND RECEPTORS, METABOLISM, PARATHYROID GLAND and PARATHYROID HORMONE.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 38 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2013 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.